5 completed, 1 not yet recruiting, 1 unknown. 7 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 7 | Completed 5, Not yet recruiting 1, Unknown 1 |
Follow Atopic Eczema: new trials by email Literature Review of Atopic Eczema trials Research Report on Atopic Eczema
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Crisaborole 2% Cream Versus Placebo in Mild to Moderate Atopic Eczema Placebo Cream, Crisaborole 2% Cream - Atopic Dermatitis (AD), Atopic Eczema | Phase 4 | Not yet recruiting | Jinnah Postgraduate Medical Centre | 270 | 2026-03-01 | 2026-03-06 |
| Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial dupilumab, Topical emollient (moisturizer) - Moderate-to-Severe Atopic Dermatitis, Atopic Eczema | Phase 4 | Completed | Regeneron Pharmaceuticals | 124 | 2023-01-11 | 2026-05-27 |
| The Effects of Topical Corticosteroid Use on Insulin Sensitivity and Bone Turnover Betnovate, betamethasone dipropionate ointment 0.1% and placebo, Protopic, tacrolimus ointment 0.1% - Atopic Dermatitis, Atopic Eczema | Phase 4 | Completed | Jacob Thyssen | 36 | 2019-08-22 | 2021-04-28 |
| Role of Anti-IgE in Severe Childhood Eczema Xolair, Placebo - Atopic Eczema, Atopic Dermatitis | Phase 4 | Completed | Guy's and St Thomas' NHS Foundation Trust | 62 | 2014-12-01 | 2019-08-09 |
| Montelukast as a Controller of Atopic Syndrome montelukast - Seasonal Allergic Rhinitis, Allergic Conjunctivitis | Phase 4 | Completed | University of Helsinki | 61 | 2007-03-01 | 2007-11-16 |
| A Quality of Life and Safety Study With Pimecrolimus Cream, 1% in Children (Age 2-12 Years) With Atopic Dermatitis Pimecrolimus cream 1% - Atopic Eczema | Phase 4 | Completed | Novartis | 2004-10-01 | 2008-02-15 | |
| Effect of Moisturizing Creams on Skin Barrier Function urea/lactic acid, Placebo - Atopic Eczema | Phase 4 | Unknown | ACO Hud Nordic AB | 2008-10-13 |
Dermatitis, Atopic (7) · Asthma (1) · Conjunctivitis, Allergic (1) · Pruritus (1) · Rhinitis, Allergic, Seasonal (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Dermatitis (7) · Genetic Diseases, Inborn (7) · Hypersensitivity (7) · Hypersensitivity, Immediate (7) · Immune System Diseases (7) · Skin Diseases (7) · Skin Diseases, Eczematous (7) · Skin Diseases, Genetic (7) · Skin and Connective Tissue Diseases (7) · Bronchial Diseases (1) · Conjunctival Diseases (1) · Conjunctivitis (1) · Eye Diseases (1) · Lung Diseases (1)
Betamethasone Valerate (1) · Emollients (1) · Omalizumab (1) · Tacrolimus (1) · crisaborole (1) · dupilumab (1) · montelukast (1) · pimecrolimus (1)
ACO Hud Nordic AB (1) · Guy's and St Thomas' NHS Foundation Trust (1) · Jacob Thyssen (1) · Jinnah Postgraduate Medical Centre (1) · Novartis (1) · Regeneron Pharmaceuticals (1) · University of Helsinki (1)
Denmark (1) · Finland (1) · South Africa (1) · Sweden (1) · United Kingdom (1) · United States (1)
Jacob P Thyssen, Professor, MD, DMSc (1) · S Chan, MBBS, MD (1) · Tari Haahtela, Professor (1)
PMID 19127072, PMID 28330497, PMID 31764962, PMID 36824052, PMID 42126851